Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01222000 |
|
Recruitment Status : Unknown
Verified October 2010 by Centre Hospitalier Universitaire de Nice.
Recruitment status was: Not yet recruiting
First Posted : October 18, 2010
Last Update Posted : October 18, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Lamellar ichthyosis (IL) is a rare autosomal recessive genodermatosis with a defect of keratinization of the skin which results in a severe generalized cutaneous xerosis with dark brown big scales, an ectropion, an eclabion, an alopecia and a palmo-plantar keratodermia. They are due to mutations of the gene TGM1 coding for the transglutaminase keratinocyte 1 (TG1) in 1/3 of the cases. Other genes were recently identified, ABCA12 coding for the triphosphate-binding adenosine cassette A12 and FLJ39501 which codes for a protein of the cytochrome p450 ( CYP4F2).
No etiological treatment is available. Symptomatic treatment consists on twice application of emollients and keratolytic ointments which decrease the dryness of the skin and reduce scales. Oral isotretinoin is usually partially effective but is only suspensive and has numerous side effects.
Recent studies showed that the epigallocatechin-3-gallate (POLYPHENON E®), extracted from green tea increases the differentiation of the normal human keratinocytes, as showedb by the increase of the involucrine, TG1 and caspase-14 genes expression.
The main objective of this pilot study is to estimate the action and the tolerance of a daily application of topical Polyphénon E 10% ® to improve the desquamation and the cutaneous roughness of patients with lamellar ichthyosis, after 4 weeks of treatment.
The secondary objectives
- To estimate the duration of remission obtained after the treatment
- To estimate the action of cutaneous Veregen® to improve the palmar and plantar involvement.
- To estimate the action of cutaneous Veregen on the pruritus
- And to estimate the global level of acceptability by the patient of the Veregen 10 %
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Lamellar Ichthyosis | Drug: apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 8 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | TREATMENT OF THE RECESSIVE NONBULLOUS CONGENITAL ICHTHYOSIS BY THE EPIGALLOCATECHINE CUTANEOUS |
| Study Start Date : | October 2010 |
| Estimated Primary Completion Date : | June 2011 |
| Estimated Study Completion Date : | June 2011 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: right controlled against moisturizing cream |
Drug: apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks. |
| Experimental: left controlled against moisturizing cream |
Drug: apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks. |
- action and the tolerance of a daily application of topical Polyphénon E 10% ® [ Time Frame: 4 weeks ]The main objective of this pilot study is to estimate the action and the tolerance of a daily application of topical Polyphénon E 10% ® to improve the desquamation and the cutaneous roughness of patients with lamellar ichthyosis, after 4 weeks of treatment.
- severity of the palmar and plantar involvement [ Time Frame: J28 ]
- level of pruritus [ Time Frame: until J28 ]
- global tolerance and acceptability by the patient of the Polyphénon E ® ointment [ Time Frame: J28 ]
- Relapse [ Time Frame: J84 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 8 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients of both sexes of at least 8 years and less than 65 years.
- Patients with a clinical diagnosis of LI
- Patients having at once a score of roughness and a desquamation of intensity moderated in severe (at least 2) on every side of the body,
- Patients and\or relatives / representatives of the parental authority in measure to understandand to follow the procedures of the study
- Consent of patient and\or parents / representatives of the parental authority
- Patient member to the Social Security
Exclusion Criteria:
- Patient of less than 8 years
- Pregnant, breast-feeding women or old enough to procreate without reliable medical contraception,
- Women with a positive pregnancy test,
- Transaminases > twice the normal.
- Patients with congenital ichthyosis others than LI,
- Patients with a erythrodermic composent,
- Patients affected by LI of the light gravity (score < 2 for the desquamation or the roughness) on at least a side of the body,
- Patients with secondary infection ,
- Patients with known allergy of to one of the ingredients contained in the tested product,
- Patients with specific topical treatment (for example analogues of vitamin A, vitamin D similar),
- Patients with topical keratolytic treatment (for example the urea, the hydroxy-acids) in 7 days before the beginning of the clinical trial
- Patients and\or relatives / representatives of the parental authority unable to understand and\or to follow the procedures of the study,
- Tea intake during the trail
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01222000
| Contact: chiaverini christine, Dr | chiaverini.c@chu-nice.fr |
| France | |
| Toulouse University Hospital, Dermatology Department | |
| Toulouse, France | |
| Principal Investigator: | Chiaverini Christine, Dr | CHU de Nice - Service de dermatologie |
| Responsible Party: | Centre Hospitalier Universitaire de Nice |
| ClinicalTrials.gov Identifier: | NCT01222000 |
| Other Study ID Numbers: |
09-PP-02 |
| First Posted: | October 18, 2010 Key Record Dates |
| Last Update Posted: | October 18, 2010 |
| Last Verified: | October 2010 |
|
Ichthyosis Ichthyosis, Lamellar Ichthyosiform Erythroderma, Congenital Skin Abnormalities Congenital Abnormalities |
Infant, Newborn, Diseases Keratosis Skin Diseases Skin Diseases, Genetic Genetic Diseases, Inborn |